# Paysign, Inc.: Form 10-Q for the period ended Jun 30, 2025

- Company: [Paysign, Inc.](/companies/pays.md) (CIK 1496443)
- Form: 10-Q
- Filed: 2025-08-06
- Accepted by EDGAR: Aug 6, 2025, 12:04 ET
- Period: 2025-06-30
- Accession: 0001683168-25-005680
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1496443/000168316825005680/paysign_i10q-063025.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1496443/000168316825005680/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2025-06-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2025-04-01 to 2025-06-30 | $19.1m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 6 months, 2025-01-01 to 2025-06-30 | $37.7m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months, 2025-04-01 to 2025-06-30 | $7.3m | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 6 months, 2025-01-01 to 2025-06-30 | $14.2m | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months, 2025-04-01 to 2025-06-30 | $11.8m | us-gaap:GrossProfit |
| Gross profit | 6 months, 2025-01-01 to 2025-06-30 | $23.4m | us-gaap:GrossProfit |
| Selling, general and administrative | 3 months, 2025-04-01 to 2025-06-30 | $8.2m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 6 months, 2025-01-01 to 2025-06-30 | $15.6m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months, 2025-04-01 to 2025-06-30 | $1.4m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months, 2025-01-01 to 2025-06-30 | $3.9m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months, 2025-04-01 to 2025-06-30 | $655.0k | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months, 2025-01-01 to 2025-06-30 | $1.3m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2025-04-01 to 2025-06-30 | $1.4m | us-gaap:NetIncomeLoss |
| Net income | 6 months, 2025-01-01 to 2025-06-30 | $4.0m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2025-04-01 to 2025-06-30 | $0.02 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months, 2025-01-01 to 2025-06-30 | $0.07 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2025-04-01 to 2025-06-30 | $0.03 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months, 2025-01-01 to 2025-06-30 | $0.07 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2025-04-01 to 2025-06-30 | 57,872,318 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months, 2025-01-01 to 2025-06-30 | 56,312,252 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months, 2025-01-01 to 2025-06-30 | −$2.4m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months, 2025-01-01 to 2025-06-30 | $164.9k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Share repurchases | 6 months, 2025-01-01 to 2025-06-30 | $375.8k | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | at 2025-06-30 | $11.8m | us-gaap:Cash |
| Current assets | at 2025-06-30 | $158.7m | us-gaap:AssetsCurrent |
| Total assets | at 2025-06-30 | $193.9m | us-gaap:Assets |
| Current liabilities | at 2025-06-30 | $143.3m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2025-06-30 | $151.7m | us-gaap:Liabilities |
| Long-term debt | at 2025-06-30 | $6.1m | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | at 2025-06-30 | $1.6m | us-gaap:LongTermDebtCurrent |
| Shareholders' equity | at 2025-06-30 | $42.2m | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 38,525 characters.

### Disclosure Regarding Forward-Looking Statements

This Quarterly Report on Form 10-Q includes forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) (“Forward-Looking Statements”). All statements other than statements of historical fact included in this report are Forward-Looking Statements. These Forward-Looking Statements are based on our current expectations, assumptions, estimates and projections about our business and our industry. Words such as “believe,” “anticipate,” “expect,” “intend,” “plan,” “propose,” “may,” and other similar expressions identify Forward-Looking statements. Specific forward-looking statements made herein include our belief that we do not anticipate any losses with respect to accounts with balances exceeding federally insured limits; our expected lease obligations for subsequent years; our belief that our platform can be seamlessly integrated with our clients’ systems; our belief that our distinctive positioning allows us to provide end-to end technologies that securely manage transaction processing, cardholder enrollment, value loading, account management, data and analytics, and customer service; our belief that our architecture is known for its cross-platform compatibility, flexibility, and scalability - allowing our clients and partners to leverage these advantages for cost savings and revenue opportunities; our focus of our marketing efforts on corporate incentive and expense prepaid card products in various market verticals; our plan for 2025 to continue to invest additional funds in technology improvements, sales and marketing, cybersecurity, fraud, customer service, and regulatory compliance; our belief that from time to time we evaluate raising capital to enable us to diversify into new market verticals; our belief that if we do not raise new capital, that we will still be able to support our existing business and expand into new vertical markets using internally generated funds; our belief that the following measures are the primary indicators of our quarterly and annual revenues: gross dollar volume on loaded cards and conversion rates on gross dollar volume loaded on cards; our belief that the following are also key performance indicators: revenues, gross profit, operational expenses as a percent of revenues, cardholder participation, and EBITDA; and our belief that our available cash on hand, excluding restricted cash, along with our forecast for revenues and cash flows for the remainder of 2025 and through the second quarter of 2027, will be sufficient to sustain our operations for the next twenty-four months. In the normal course of our business, we, in an effort to help keep our stockholders and the public informed about our operations, may from time-to-time issue certain statements, either in writing or orally, that contain, or may contain, Forward-Looking Statements. Although we believe that the expectations reflected in such Forward-Looking Statements are reasonable, we can give no assurance that such expectations will prove to have been correct. In addition, any statements that refer to expectations, projections, estimates, forecasts, or other characterizations of future events or circumstances are Forward-Looking Statements. These Forward-Looking Statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those reflected in the Forward-Looking Statements. Such important factors (“Important Factors”) and other factors are disclosed under “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2024 and in other reports filed with the Securities and Exchange Commission (the “SEC”) from time to time. All prior and subsequent written and oral Forward-Looking Statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by the Important Factors described below that could cause actual results to differ materially from our expectations as set forth in any Forward-Looking Statement made by or on behalf of us. You are cautioned not to place undue reliance on these Forward-Looking Statements, which relate only to events as of the date on which the statements are made. We undertake no obligation to publicly revise these Forward-Looking Statements to reflect events or circumstances that arise after the date hereof. You should refer to and carefully review the information in future documents we file with the SEC.

### Overview

Paysign, Inc. (the “Company,” “Paysign,” “we” or “our”), headquartered in Nevada, was incorporated on August 24, 1995, and trades under the symbol PAYS on The Nasdaq Stock Market LLC. We are a vertically integrated provider of prepaid card products and processing services for corporate, consumer and government applications. Our payment solutions are utilized by our corporate customers as a means to increase customer loyalty, increase patient adherence rates, reduce administration costs and streamline operations. Public sector organizations can utilize our payment solutions to disburse public benefits or for internal payments. We market our prepaid card solutions under our Paysign® brand. As we are a payment processor and prepaid card program manager, we derive our revenue from all stages of the prepaid card lifecycle.

We operate on a powerful, high-availability payments platform with cutting-edge fintech capabilities that can be seamlessly integrated with our clients’ systems. This distinctive positioning allows us to provide end-to-end technologies that securely manage transaction processing, cardholder enrollment, value loading, account management, data and analytics, and customer service. Our architecture is known for its cross-platform compatibility, flexibility, and scalability – allowing our clients and partners to leverage these advantages for cost savings and revenue opportunities.

Our suite of product offerings includes solutions for corporate rewards, prepaid gift cards, general purpose reloadable debit cards, employee incentives, consumer rebates, donor compensation, clinical trials, healthcare reimbursement payments and pharmaceutical payment assistance, and demand deposit accounts accessible with a debit card. Our cards are sponsored by our issuing bank partners.

Our revenues include fees generated from cardholder fees, interchange, card program management fees, transaction claims processing fees, breakage, and settlement income. Revenue from cardholder fees, interchange, card program management fees, and transaction claims processing fees is recorded when the performance obligation is fulfilled. Breakage is recorded ratably over the estimated card life based on historical redemption patterns, market-specific trends, escheatment rules, and existing economic conditions and relates solely to our open-loop gift card business which began at the end of 2022. Settlement income is recorded at the expiration of the card and card program.

We have two categories for our prepaid debit cards: (1) corporate and consumer reloadable cards, and (2) non-reloadable cards.

Reloadable Cards: These types of cards are generally classified as payroll or general purpose reloadable (“GPR”) cards. Payroll cards are issued by an employer to an employee to allow the employee to access payroll amounts that are deposited into an account linked to their card. GPR cards can also be issued to a consumer at a retail location or mailed to a consumer after completing an on-line application. GPR cards can be reloaded multiple times with a consumer’s payroll, government benefit, a federal or state tax refund or through cash reload networks located at retail locations. Reloadable cards are generally open-loop cards as described below.

Non-Reloadable Cards: These are generally one-time use cards that are only active until the funds initially loaded to the card are spent. These types of cards are generally used as gift or incentive cards. Typically, these types of cards are used for the purchase of goods or services at retail locations and cannot be used to receive cash.

Both reloadable and non-reloadable cards may be open-loop, closed-loop, or restricted-loop. Open-loop cards can be used to receive cash at ATM locations utilizing a customer’s primary identification number (“PIN”); or purchase goods or services by PIN or signature at retail locations virtually anywhere that the network brand (American Express, Discover, Mastercard, Visa, etc.) is accepted. Closed-loop cards can only be used at a specific merchant. Restricted-loop cards can be used at several merchants, or a defined group of merchants, such as all merchants at a specific shopping mall.

The prepaid card market in the United States has experienced significant growth in recent years due to consumers and merchants embracing improved technology, greater convenience, more product choices and greater flexibility. Prepaid cards have also proven to be an attractive alternative to traditional bank accounts for certain segments of the population, particularly those without, or who could not qualify for, a checking or savings account.

We manage all aspects of the prepaid card lifecycle, from managing the card design and approval processes with partners and networks, to production, packaging, distribution, and personalization. We also oversee inventory and security controls, renewals, lost and stolen card management, and replacement. We employ a 24/7/365 fully staffed, in-house customer service department which utilizes bilingual customer service representatives, Interactive Voice Response, and two-way short message service messaging and text alerts.

Currently, we are focusing our marketing efforts on corporate incentive and expense prepaid card products in various market verticals including but not limited to general corporate expense, healthcare related markets including pharma patient affordability solutions, clinical trials and donor compensation, loyalty rewards, and incentive cards. Following the acquisition of Gamma, we are now allocating some of our marketing efforts to selling our donor engagement application and customer resource management product into our existing markets.

As part of our continuing platform expansion process, we evaluate current and emerging technologies for applicability to our existing and future software platform. To this end, we engage with various hardware and software vendors in evaluation of various infrastructure components. Where appropriate, we use third-party technology components in the development of our software applications and service offerings. Third-party software may be used for highly specialized business functions, which we may not be able to develop internally within time and budget constraints. Our principal target markets for processing services include prepaid card issuers, retail and private-label issuers, small third-party processors, and small and mid-size financial institutions in the United States and Mexico.

We have devoted more extensive resources to sales and marketing activities as we have added essential personnel to our marketing, sales and support teams. We market our Paysign payment and application solutions through direct marketing by the Company’s sales team. Our primary market focus is on companies that require a streamlined payment solution for rewards, rebates, payment assistance, and other payments to their customers, employees, agents and others. To reach these markets, we focus our sales efforts on direct contact with our target market and attendance at various industry specific conferences. We may, at times, utilize independent contractors who make direct sales and are paid commissions and/or restricted stock awards. We market our Paysign premier product through existing communication channels to a targeted segment of our existing cardholders, as well as to a broad group of individuals, ranging from non-banked to fully banked consumers with a focus on long term users of our product.

In 2025, we plan to continue to invest additional funds in technology improvements, sales and marketing, cybersecurity, fraud, customer service, and regulatory compliance. From time to time, we evaluate raising capital to enable us to diversify into new market verticals. If we do not raise new capital, we believe that we will still be able to support our existing business and expand into new vertical markets using internally generated funds.

### Results of Operations

#### Comparison of the Three Months Ended June 30, 2025 to the Three Months Ended June 30, 2024

The following table summarizes our consolidated financial results for the three months ended June 30, 2025 in comparison to the three months ended June 30, 2024:

| Revenues | Three Months Ended June 30, (Unaudited) 2025 | 2024 | Variance $% |  |
| --- | ---: | ---: | ---: | ---: |
| Plasma industry | $10,743,924 | $11,273,262 | $(529,338) | (4.7%) |
| Pharma industry | 7,753,906 | 2,674,901 | 5,079,005 | 189.9% |
| Other | 580,523 | 383,436 | 197,087 | 51.4% |
| **Total revenues** | 19,078,353 | 14,331,599 | 4,746,754 | 33.1% |
| **Cost of revenues** | 7,323,188 | 6,745,836 | 577,352 | 8.6% |
| **Gross profit** | 11,755,165 | 7,585,763 | 4,169,402 | 55.0% |
| **Gross margin %** | 61.6% | 52.9% |  |  |
| **Operating expenses** |  |  |  |  |
| Selling, general and administrative | 8,197,461 | 6,020,464 | 2,176,997 | 36.2% |
| Depreciation and amortization | 2,120,097 | 1,439,622 | 680,475 | 47.3% |
| **Total operating expenses** | 10,317,558 | 7,460,086 | 2,857,472 | 38.3% |
| **Income from operations** | $1,437,607 | $125,677 | $1,311,930 | 1043.9% |
| **Other income** | $605,160 | $813,357 | $(208,197) | (25.6%) |
| **Net income** | $1,387,761 | $697,102 | $690,659 | 99.1% |
| **Net margin %** | 7.3% | 4.9% |  |  |

21

The increase in total revenues of $4,746,754 for the three months ended June 30, 2025 compared to the same period in the prior year consisted primarily of a $529,338 decrease in plasma revenue, a $5,079,005 increase in pharma revenue, and a $197,087 increase in other revenue. The decrease in plasma revenue was primarily due to a decline in plasma donations and dollars loaded to cards as plasma inventory levels have normalized, which has reduced our average monthly revenue per center as compared to the same period in the prior year. This decline was offset by the addition of 123 net plasma centers during the second quarter of 2025, all of which went live June 16, 2025. The increase in pharma revenue was primarily due to the financial benefit of 33 net pharma patient affordability programs launched throughout 2024 and subsequent full year impact in the second quarter of 2025, the launch of seven (7) net pharma patient affordability programs in the second quarter of 2025, and a corresponding increase in monthly management fees, setup fees, claim processing fees, and other billable services such as dynamic business rules and call center support. The number of claims processed increased over 80% in the second quarter of 2025 compared to the same period in the prior year. The increase in other revenue was primarily due to the growth and usage in the number of cardholders of our payroll, retail, and corporate incentive programs.

Cost of revenues for the three months ended June 30, 2025 increased $577,352 compared to the same period in the prior year. Cost of revenues is comprised of transaction processing fees, data connectivity and data center expenses, network fees, bank fees, card production and postage costs, customer service, program management, application integration setup, and sales and commission expense. The increase in cost of revenues consisted primarily of (i) increased customer care expense of approximately $355,000 associated primarily with the growth in our pharma patient affordability programs, wage inflation pressures, a tight labor market, and increased benefit costs; (ii) increased third-party program management fees of approximately $230,000 associated with our pharma patient affordability programs; (iii) increased plastics, collateral and postage of approximately $270,000 that was primarily associated with our plasma programs; and (iv) increased sales commission expense of approximately $211,000 related to the increase in overall revenue for programs in which we pay commission expenses. These increases were offset predominantly by decreased usage of our card programs and related fees of approximately $396,000 in network fees and approximately $93,000 of rebate costs due to lower plasma volumes.

Gross profit for the three months ended June 30, 2025 increased $4,169,402 compared to the same period in the prior year, resulting primarily from the launch of an additional seven (7) net programs in the second quarter of 2025, a full year financial benefit of programs launched in 2024, and a corresponding increase in setup fees, monthly management fees, claim processing fees, and other billable fees associated with our pharma patient affordability programs. Gross profit also benefited from our plasma revenue and the beneficial impact of a variable cost structure, as many of the plasma transaction costs are variable in nature and are provided by third-parties who charge us based on the number of active cards outstanding and transactions that occurred during the period. The increase in gross profit was offset by one-time upfront costs associated with the 123 new plasma centers that went live on June 16, 2025, increased costs from third-party service providers, sales commission expense and customer service costs mentioned above, primarily driven by the overall growth in our business. The increase in gross margin resulted primarily from a greater contribution of total revenue from our pharma patient affordability business which has higher gross profit margins than our other businesses.

Selling, general and administrative expenses for the three months ended June 30, 2025 increased $2,176,997 compared to the same period in the prior year and consisted primarily of an increase in (i) compensation and benefits of approximately $974,000 due to continued hiring to support our growth primarily from our pharma patient affordability business, a tight labor market, and increased benefit costs; (ii) technologies and telecom of approximately $299,000 primarily related to ongoing platform security investments; (iii) stock-based compensation costs of approximately $284,000; (iv) general expenses of approximately $141,000 primarily related to conferences, deliveries, and employee education; (v) outside professional services of approximately $61,000 for audit, tax, and human resources; and (vi) other expenses of approximately $49,000 as well as a $369,000 decrease in the amount of platform development costs that were capitalized.

Depreciation and amortization expense for the three months ended June 30, 2025 increased $680,474 compared to the same period in the prior year. The increase in depreciation and amortization expense was primarily due to continued capitalization of new software development costs and equipment purchases related to continued enhancements to our processing platform and employment growth.

For the three months ended June 30, 2025, we recorded income from operations of $1,437,607 representing an improvement of $1,311,930 compared to income from operations of $125,677 during the same period in the prior year, related to the aforementioned factors.

Other income for the three months ended June 30, 2025 decreased $208,197 primarily related to the implied interest expense related to future cash payments for the Gamma acquisition of $129,173 and slightly lower interest rates and average bank account balances primarily from our plasma customers at our sponsor bank.

At June 30, 2025, our income tax provision was $655,006, which was based on our net operating income adjusted for discrete items that occurred withing the quarter. The effective tax rate of 32.1% compared to 25.8% reflects the impact of discrete items related to the appreciation of our stock price during our second quarter of 2025.

The net income for the three months ended June 30, 2025 was $1,387,761, an increase of $690,659 compared to the net income of $697,102 for the three months ended June 30, 2024. The overall change in net income relates to the aforementioned factors.

#### Comparison of the Six Months Ended June 30, 2025 to the Six Months Ended June 30, 2024

The following table summarizes our consolidated financial results for the six months ended June 30, 2025 in comparison to the six months ended June 30, 2024:

| Revenues | Six Months Ended June 30, (Unaudited) 2025 | 2024 | Variance $% |  |
| --- | ---: | ---: | ---: | ---: |
| Plasma industry | $20,153,804 | $21,641,296 | $(1,487,492) | (6.9%) |
| Pharma industry | 16,372,559 | 5,063,545 | 11,309,014 | 223.3% |
| Other | 1,150,139 | 816,832 | 333,307 | 40.8% |
| **Total revenues** | 37,676,502 | 27,521,673 | 10,154,829 | 36.9% |
| **Cost of revenues** | 14,230,509 | 12,996,659 | 1,233,850 | 9.5% |
| **Gross profit** | 23,445,993 | 14,525,014 | 8,920,979 | 61.4% |
| **Gross margin %** | 62.2% | 52.8% |  |  |
| **Operating expenses** |  |  |  |  |
| Selling, general and administrative | 15,598,220 | 11,931,662 | 3,666,558 | 30.7% |
| Depreciation and amortization | 3,921,100 | 2,726,027 | 1,195,073 | 43.8% |
| **Total operating expenses** | 19,519,320 | 14,657,689 | 4,861,631 | 33.2% |
| **Income (loss) from operations** | $3,926,673 | $(132,675) | $4,059,348 | NM |
| **Other income** | $1,367,358 | $1,544,701 | $(177,343) | (11.7%) |
| **Net income** | $3,973,861 | $1,006,198 | $2,967,663 | 294.9% |
| **Net margin %** | 10.5% | 3.7% |  |  |

23

The increase in total revenues of $10,154,829 for the six months ended June 30, 2025 compared to the same period in the prior year consisted primarily of a $1,487,492 decrease in plasma revenue, an $11,309,014 increase in pharma revenue, and a $333,307 increase in other revenue. The decrease in plasma revenue was primarily due to a decline in plasma donations and dollars loaded to cards as plasma inventory levels have normalized, which has reduced our average monthly revenue per center as compared to the same period in the prior year. This decline was offset by the addition of 127 net plasma centers during the first two quarters of 2025, 123 of which went live June 16, 2025. The increase in pharma revenue was primarily due to the financial benefit of 33 net pharma patient affordability programs launched throughout 2024 and subsequent full year impact in the first half of 2025, the launch of 21 net pharma patient affordability programs in the first half of 2025, and a corresponding increase in monthly management fees, setup fees, claim processing fees, and other billable services such as dynamic business rules and call center support. The number of claims processed increased over 110% in the first half of 2025 compared to the same period in the prior year. The increase in other revenue was primarily due to the growth and usage in the number of cardholders of our payroll, retail, and corporate incentive programs.

Cost of revenues for the six months ended June 30, 2025 increased $1,233,850 compared to the same period in the prior year. Cost of revenues is comprised of transaction processing fees, data connectivity and data center expenses, network fees, bank fees, card production and postage costs, customer service, program management, application integration setup, and sales and commission expense. The increase in cost of revenues consisted primarily of (i) increased customer care expense of approximately $734,000 associated primarily with the growth in our pharma patient affordability programs, wage inflation pressures, a tight labor market, and increased benefit costs; (ii) increased third-party program management fees of approximately $581,000 associated with our pharma patient affordability programs; (iii) increased plastics, collateral and postage of approximately $228,000; and (iv) increased sales and commission expense of approximately $467,000 related to the increase in overall revenue for programs in which we pay commission expenses. These increases were offset predominantly by decreased usage of our card programs and related fees of approximately $521,000 in network fees, reduced rebate fees of approximately $208,000 due to lower plasma volumes, and other costs of approximately $49,000.

Gross profit for the six months ended June 30, 2025 increased $8,920,979 compared to the same period in the prior year resulting primarily from the launch of an additional 21 net programs in the first two quarters of 2025, a full year financial benefit of programs launched in 2024, and a corresponding increase in setup fees, monthly management fees, claim processing fees, and other billable fees associated with our pharma patient affordability programs. Gross profit also benefited from our plasma revenue and the beneficial impact of a variable cost structure, as many of the plasma transaction costs are variable in nature and are provided by third parties who charge us based on the number of active cards outstanding and transactions that occurred during the period. The increase in gross profit was offset by one-time upfront costs associated with the 123 new plasma centers that went live on June 16, 2025, increased costs from third-party service providers, sales and commission expense, and customer service costs mentioned above, primarily driven by the overall growth in our business. The increase in gross margin resulted primarily from a greater contribution of total revenue from our pharma patient affordability business which has higher gross profit margins than our other businesses.

Selling, general and administrative expenses for the six months ended June 30, 2025 increased $3,666,558 compared to the same period in the prior year and consisted primarily of an increase in (i) compensation and benefits of approximately $2,519,000 due to continued hiring to support our growth, a tight labor market, and increased benefit costs; (ii) technologies and telecom expense of approximately $631,000 primarily related to ongoing platform security investments; (iii) acquisition costs of approximately $129,000 associated with the Gamma asset purchase; (iv) stock-based compensation of approximately $293,000; (v) travel and entertainment of approximately $76,000; and (vi) all other operating expenses of approximately $19,000.

Depreciation and amortization expense for the six months ended June 30, 2025 increased $1,195,073 compared to the same period in the prior year. The increase in depreciation and amortization expense was primarily due to continued capitalization of new software development costs and equipment purchases related to continued enhancements to our processing platform and employment growth.

For the six months ended June 30, 2025, we recorded income from operations of $3,926,673 representing an improvement of $4,059,348 compared to a loss from operations of $132,675 during the same period in the prior year related to the aforementioned factors.

Other income for the six months ended June 30, 2024 decreased $177,343 primarily related to the implied interest expense related to future cash payments for the Gamma acquisition of $129,173 and slightly lower interest rates and average bank account balances primarily from our plasma customers at our sponsor bank.

At June 30, 2025, our income tax expense was $1,320,170, which equates to an effective tax rate of 24.9% primarily as a result of tax benefits related to our stock-based compensation. At June 30, 2024, our income tax expense was $405,828, which equates to an effective tax rate of 28.7% primarily as a result of tax benefits related to our stock-based compensation and changes to our valuation allowance recorded on our net deferred tax assets.

The net income for the six months ended June 30, 2025 was $3,973,861, an improvement of $2,967,663 compared to the net income of $1,006,198 for the six months ended June 30, 2024. The overall change in net income relates to the aforementioned factors.

### Key Performance Indicators and Non-GAAP Measures

Management reviews a number of metrics to help us monitor the performance of and identify trends affecting our business. We believe the following measures are the primary indicators of our quarterly and annual revenues:

Gross Dollar Volume Loaded on Cards: Represents the total dollar volume of funds loaded to all our prepaid card programs. Our gross dollar volume loaded on cards was $440 million and $456 million for the three months ended June 30, 2025 and 2024, respectively. Our gross dollar volume loaded on cards was $847 million and $882 million for the six months ended June 30, 2025 and 2024, respectively. We use this metric to analyze the total amount of money moving into our prepaid card programs. The year over year decline reflects the decline in loads we are experiencing in our plasma programs, partially offset by growth in our pharma patient affordability and other prepaid programs.

Conversion Rates on Gross Dollar Volume Loaded on Cards: Represents revenues, gross profit or net income (loss) conversion rates of gross dollar volume loaded on cards which are calculated by taking our total revenues, gross profit or net income (loss), respectively, as a numerator and dividing by the gross dollar volume loaded on cards as a denominator. As we derive a number of our financial results from cardholder fees, we utilize these metrics as an indication of the amount of money that is added to cards and will eventually be converted to revenues, gross profit and net income (loss). Our total revenue conversion rates for the three months ended June 30, 2025 and 2024 were 4.34% or 434 basis points (“bps”), and 3.14% or 314 basis points, respectively, of gross dollar volume loaded on cards. Our total gross profit conversion rates for the three months ended June 30, 2025and 2024 were 2.67% or 267 bps, and 1.66% or 166 bps, respectively, of gross dollar volume loaded on cards. Our net income (loss) conversion rates for the three months ended June 30, 2025 and 2024 were 0.32% or 32 bps, and 0.15% or 15 bps, respectively, of gross dollar volume loaded on cards. Our total revenue conversion rates for the six months ended June 30, 2025 and 2024 were 4.45% or 445 bps, and 3.12% or 312 bps, respectively, of gross dollar volume loaded on cards. Our total gross profit conversion rates for the six months ended June 30, 2025 and 2024 were 2.77% or 277 bps, and 1.65% or 165 bps, respectively, of gross dollar volume loaded on cards. Our net income (loss) conversion rates for the six months ended June 30, 2025 and 2024 were 0.47% or 47 bps, and 0.11% or 11 bps, respectively, of gross dollar volume loaded on cards.

Management also reviews key performance indicators, such as revenues, gross profit, operational expenses as a percentage of revenues, and cardholder participation. In addition, we consider certain non-GAAP (or “adjusted”) measures to be useful to management and investors evaluating our operating performance for the periods presented and provide a financial tool for evaluating our ongoing operations, liquidity and management of assets. This information can assist investors in assessing our financial performance and measures our ability to generate capital for deployment and investment in new card programs. These adjusted metrics are consistent with how management views our business and are used to make financial, operating and planning decisions. These metrics, however, are not measures of financial performance under GAAP and should not be considered a substitute for revenue, operating income, net income (loss), earnings (loss) per share (basic and diluted) or net cash from operating activities as determined in accordance with GAAP. We consider the following non-GAAP measures, which may not be comparable to similarly titled measures reported by other companies, to be key performance indicators:

“EBITDA” is defined as earnings before interest, income taxes, depreciation and amortization expense and “Adjusted EBITDA” reflects the adjustment to EBITDA to exclude stock-based compensation expense. A reconciliation of net income to Adjusted EBITDA is provided in the table below.

| Reconciliation of Adjusted EBITDA to net income: | Three Months Ended June 30, 2025 | 2024 | Six Months Ended June 30, 2025 | 2024 |
| --- | ---: | ---: | ---: | ---: |
| **Net income** | $1,387,761 | $697,102 | $3,973,861 | $1,006,198 |
| Income tax provision | 655,006 | 241,932 | 1,320,170 | 405,828 |
| Interest income, net | (605,160) | (813,357) | (1,367,358) | (1,544,701) |
| Depreciation and amortization | 2,120,097 | 1,439,622 | 3,921,100 | 2,726,027 |
| **EBITDA** | 3,557,704 | 1,565,299 | 7,847,773 | 2,593,352 |
| Stock-based compensation | 954,400 | 670,138 | 1,626,718 | 1,334,089 |
| **Adjusted EBITDA** | $4,512,104 | $2,235,437 | $9,474,491 | $3,927,441 |

“EBITDA margin” is defined as earnings before interest, income taxes, depreciation and amortization expense as a percentage of the Company’s revenue and “Adjusted EBITDA margin” reflects the adjustment to EBITDA margin to exclude stock-based compensation expense as a percentage of revenue. A reconciliation of net income margin to Adjusted EBITDA margin is provided in the table below.

| Reconciliation of adjusted EBITDA margin to net income margin: | Three Months Ended June 30, 2025 | 2024 | Six Months Ended June 30, 2025 | 2024 |
| --- | ---: | ---: | ---: | ---: |
| **Net income margin** | 7.3% | 4.9% | 10.5% | 3.7% |
| Income tax provision | 3.4% | 1.7% | 3.5% | 1.5% |
| Interest income, net | (3.2%) | (5.7%) | (3.6%) | (5.6%) |
| Depreciation and amortization | 11.1% | 10.0% | 10.4% | 9.9% |
| **EBITDA margin** | 18.6% | 10.9% | 20.8% | 9.4% |
| Stock-based compensation | 5.0% | 4.7% | 4.3% | 4.8% |
| **Adjusted EBITDA margin** | 23.7% | 15.6% | 25.1% | 14.3% |

### Liquidity and Capital Resources

The following table sets forth the major sources and uses of cash:

|  | Six Months Ended June 30, (Unaudited) 2025 | 2024 |
| --- | ---: | ---: |
| Net cash (used in) provided by operating activities | $(2,392,276) | $28,796,693 |
| Net cash used in investing activities | (6,253,535) | (4,640,045) |
| Net cash provided by financing activities | 215,748 | 24,000 |
| Net (decrease) increase in cash and restricted cash | $(8,430,063) | $24,180,648 |

26

#### Comparison of Six Months Ended June 30, 2025 and 2024

During the six months ended June 30, 2025 and 2024, we financed our operations through internally generated funds.

Operating activities used $8,430,063 of cash as of June 30, 2025, a decrease of $31,188,969 compared to same period in the prior year. This change in cash flow compared to the prior period is primarily due to net decreases in operating assets and liabilities. The changes in accounts receivable, accounts payable, and customer card funding, a net decrease of $37,251,978, are primarily related to the growth in our pharma patient affordability business and timing of pass-through payments as we are invoiced by third-party service providers at the end of the period and are due monies from our pharma patient affordability customers to cover these third-party payables. The decrease in cash flows from operating activities was offset by an increase in net income, reduced prepaid expenses, collection of tax credits and non-cash adjustments for depreciation and amortization, deferred income tax, stock-based compensation, loan expense and lease expense.

We used net cash in investing activities during the six months ended June 30, 2025 and 2024 of $6,253,535 and $4,640,045, respectively. For the six months ended June 30, 2025, $4,253,535 of the cash was used for investing activities primarily attributable to an increase in software licenses and the capitalization of internally developed software as we continue to invest in our technology platform. The remaining amount of $2,000,000 was used for the Gamma acquisition that closed on March 19, 2025 (see “Note 2- ACQUISITION” in the notes to the accompanying consolidated financial statements).

Cash provided by financing activities of $215,748 for the six months ended June 30, 2025 was primarily attributed to proceeds from the exercise of options of $591,534, partially offset by the repurchase of 100,000 shares of the Company’s common stock at a weighted average price of $3.76 per share.

Our significant contractual cash requirements also include ongoing payments for lease liabilities and acquisition. For additional information regarding our cash commitments and contractual obligations, see “Note 2 – ACQUISITION” and “Note 5 – LEASE” in the notes to the accompanying consolidated financial statements.

### Sources of Liquidity

We believe that our available cash on hand, excluding restricted cash, at June 30, 2025 of $11,753,184, along with our forecast for revenues and cash flows for the remainder of 2025 and through the second quarter of 2027, will be sufficient to sustain our operations for the next twenty-four months. In light of the recent bank failures, we continue to monitor the health and soundness of our bank relationships through publicly available information. Based on recent SEC filings, we have not discovered any issues that would cause us to alter our bank relationships.

### Critical Accounting Policies and Estimates

Our significant accounting policies are described in Note 2 of the Notes to Consolidated Financial Statements of our Annual Report on Form 10-K for the fiscal year ended December 31, 2024.

The preparation of consolidated financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.

Our estimates are based on our experience and our interpretation of economic, political, regulatory, and other factors that affect our business prospects. Actual results may differ significantly from our estimates.

## Controls and procedures

As filed, 1,429 characters.

### Disclosure Controls and Procedures

Disclosure controls and procedures means controls and other procedures that are designed to ensure that the information we are required to disclose in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and to ensure that information required to be disclosed by us in those reports is accumulated and communicated to our management, including our principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. Our chief executive officer and chief financial officer evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of June 30, 2025. Based on that evaluation, our chief executive officer and chief financial officer have concluded that our disclosure controls and procedures were effective as of June 30, 2025, the end of the period covered by this Quarterly Report on Form 10-Q.

### Changes in Internal Control over Financial Reporting

During the quarter ended June 30, 2025, there have been no changes in our internal control over financial reporting that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Filed Aug 6, 2025.
Source: SEC EDGAR, the filing index for accession 0001683168-25-005680. Last ingested by Listed: Oct 24, 2026, 15:07 ET. No prices; not investment advice.